We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Magnolia Compound Is a Potent Anti-Cancer Agent

By Biotechdaily staff writers
Posted on 22 Jul 2008
Print article
Cancer researchers have shown that honokiol, a compound isolated from magnolia suppresses tumor growth by inhibiting the activity of the enzyme phospholipase D (PLD).

Honokiol is a biphenolic molecule present in the cones, bark, and leaves of Magnolia grandiflora that has been used in traditional Japanese medicine as an anxiolytic, anti-thrombotic, anti-depressant, anti-emetic, and anti-bacterial. While early research on the effective compounds in traditional remedies simply used whole magnolia bark extracts, known as houpu magnolia, more recent work has identified honokiol and its structural isomer magnolol as the active compounds in magnolia bark.

Elevated phospholipase D (PLD) activity provides a survival signal in several human cancer cell lines and suppresses apoptosis when cells are subjected to the stress of serum withdrawal. The tumor promoting effects of PLD are lined to the activity of RAS, which drives molecular pumps that remove chemotherapy drugs from cancer cells.

Investigators at the Emory University School of Medicine (Atlanta, GA, USA) used human cell lines growing in culture to evaluate the dependence of PLD survival signals on Ras and the effect of honokiol on Ras activation.

Results published in the July 2008 issue of the journal Clinical Cancer Research revealed that PLD activity was commonly elevated in response to the stress of serum withdrawal, and that the stress-induced increase in PLD activity was selectively suppressed by honokiol. The stress-induced increase in PLD activity was accompanied by increased Ras activation, and the stress-induced increase in PLD activity in MDA-MB-231 breast cancer cells was dependent on a Ras. These results allowed the authors to conclude that honokiol may be a valuable therapeutic reagent for targeting a large number of human cancers that depend on Ras and PLD for their survival.

"Knowing more about how honokiol works will tell us what kinds of cancer to go after,” said senior author Dr. Jack Arbiser, associate professor of dermatology at Emory University School of Medicine. "We found that it is particularly potent against tumors with activated Ras. Honokiol could be effective as a way to make tumors more sensitive to traditional chemotherapy.”


Related Links:
Emory University School of Medicine
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The AI model accurately classifies pediatric sarcomas using digital pathology images alone (Photo courtesy of Shutterstock)

AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping

Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.